Figure 1. High lncRNA FAM181A-AS1 expression correlates with poor prognosis of glioma patients. (A) TCGA and GTEx database analyses show FAM181A-AS1 expression in glioma (n=163) and non-cancerous brain tissue samples (n=207). (B) CGGA database analysis shows FAM181A-AS1 expression in WHO stage II/III (n=105) and WHO stage IV (n=109) glioma patients. (C) CGGA database analysis shows FAM181A-AS1 expression in glioma patients with wild-type (n=175) or mutant IDH genotypes (n=33). (D) Kaplan-Meier survival curve analysis shows overall survival of glioma patients with high or low FAM181A-AS1 expression. (E) ROC curves analysis shows the sensitivity and specificity of FAM181A-AS1 expression in glioma samples. Note: *P<0.05, ***P<0.001; data are represented as means ± SD.